Halozyme Therapeutics (NASDAQ:HALO) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported $0.85 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.27, Briefing.com reports. The firm had revenue of $189.60 million for the quarter, compared to analysts’ expectations of $173.11 million. Halozyme Therapeutics had a negative return on equity of 892.57% and a negative net margin of 53.17%. The company’s quarterly revenue was up 386.2% compared to the same quarter last year. During the same quarter last year, the business earned ($0.21) EPS.
Shares of Halozyme Therapeutics (NASDAQ HALO) opened at $18.48 on Wednesday. The stock has a market capitalization of $2,639.30, a price-to-earnings ratio of -27.18 and a beta of 1.99. Halozyme Therapeutics has a 1-year low of $11.41 and a 1-year high of $21.13. The company has a current ratio of 3.46, a quick ratio of 3.37 and a debt-to-equity ratio of 2.01.
Several research analysts have weighed in on HALO shares. BMO Capital Markets increased their price objective on Halozyme Therapeutics from $15.00 to $18.00 and gave the stock a “market perform” rating in a research report on Wednesday, November 8th. Canaccord Genuity increased their price objective on Halozyme Therapeutics from $17.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, November 8th. Barclays cut Halozyme Therapeutics from an “overweight” rating to a “hold” rating and increased their price objective for the stock from $16.00 to $19.00 in a research report on Wednesday, November 22nd. BidaskClub cut Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 5th. Finally, Zacks Investment Research upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $22.00 price objective on the stock in a research report on Tuesday, December 12th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $19.25.
ILLEGAL ACTIVITY WARNING: “Halozyme Therapeutics (HALO) Issues Quarterly Earnings Results” was originally published by Stock Observer and is the sole property of of Stock Observer. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.thestockobserver.com/2018/02/21/halozyme-therapeutics-halo-issues-quarterly-earnings-results.html.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.